ESR1 and cancer: To complement the experimental cytotoxicity screening, we conducted in silico molecular docking studies to predict the binding interactions of these derivatives with the key cancer-related targets, including Topoisomerase II, VEGFR2, c-Met, EGFR, and ERα.